Supplementary Table 3 Characteristics of the COVID-19 and non-COVID-19 cohorts for gut microbiome analysis

Cohorts	COVID-19	Non-COVID-19
Number, n	68	68
Female, n (%)	34 (50%)	36 (52.9%)
Median age, mean ± SD*	49 ± 17.7	47.2 ± 16.8
Comorbidities, n (%)		
Hypertension	12 (17.6%)	11 (16.2%)
Hyperlipidaemia	7 (10.3%)	10 (14.7%)
Diabetes	9 (13.23%)	9 (13.23%)
Antibiotic therapy, n (%)	18 (26.5%)	0
Antiviral therapy, n (%)		
Lopinavir/Ritonavir	40 (58.8%)	0
Ribavirin	33 (48.6%)	0
Interferon Beta-1B	21 (30.9%)	0
Disease Severity Category, n (%)		
Mild	18 (26.5%)	NA
Moderate	34 (50%)	NA
Severe	10 (14.7%)	NA
Critical	6 (8.8%)	NA
PACS, n (%)	50 (73.5 %)	NA

* $p = 0.796$

Abbreviations: NA, not available